Full Breakdown
New Pill Zasocitinib Shows Promise for Plaque Psoriasis Treatment
4/2/2026, 10:57:23 PM
Breakthrough in Psoriasis Management
Recent clinical trial results indicate that a new oral medication, zasocitinib, may revolutionize the treatment of moderate-to-severe plaque psoriasis. Traditionally, patients have faced a choice between less effective oral medications and highly effective injectable therapies. Zasocitinib, developed by Takeda Pharmaceuticals, is currently in the final stages of clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA).
Clinical Trial Findings
The findings from two late-stage clinical trials, which involved nearly 1,800 adults across 21 countries, were presented at the American Academy of Dermatology meeting in Denver. Approximately 70% of participants taking zasocitinib achieved clear or nearly clear skin within 16 weeks. In comparison, only about 30% of patients on apremilast, an existing oral treatment, reported significant skin improvement. Notably, many patients began to see improvements as early as four weeks into the treatment, and over 90% of those who achieved clear skin at the nine-month mark maintained these results after more than a year of daily use.
Safety Profile
The trials reported no new or unexpected safety concerns associated with zasocitinib. The most common side effects were mild, including upper respiratory infections akin to the common cold. Additionally, about 6.5% of patients experienced acne, a known side effect of TYK2 inhibitors, the class of medication to which zasocitinib belongs.
Official Statements & Future Plans
Dr. Melinda Gooderham, the lead researcher and a dermatologist in Ontario, emphasized that the results demonstrate the potential for a daily pill to provide rapid and lasting relief for psoriasis patients, a goal previously achieved primarily through injectable therapies. Dr. Chinweike Ukomadu, a senior vice president at Takeda, stated, “Our Phase 3 results demonstrate that highly selective TYK2 inhibition can offer many people with moderate-to-severe plaque psoriasis the potential for clear or nearly clear skin.” Takeda plans to submit zasocitinib for FDA approval within the next year.
Criticism & Opposition
While the results are promising, it is important to note that findings presented at medical conferences are considered preliminary until published in a peer-reviewed journal. This raises questions about the long-term efficacy and safety of zasocitinib, which may be scrutinized further as the drug moves toward regulatory approval.
What's Next
As Takeda Pharmaceuticals prepares to submit zasocitinib for FDA approval, the medical community and patients alike await further developments regarding its potential availability and impact on psoriasis treatment options.
